By Hans G. Vogel
The recent version of this winning reference bargains either state-of-the-art and vintage pharmacological tools. completely revised and multiplied to 2 volumes, it bargains an up to date number of the main usually used assays for reliably detecting the pharmacological results of capability medicines. each bankruptcy has been up-to-date, and diverse assays were additional. all the greater than 1,000 assays includes an in depth protocol outlining goal and motive, and a serious evaluation of the consequences and their pharmacological and medical relevance.
Read Online or Download Drug Discovery and Evaluation: Pharmacological Assays PDF
Similar toxicology books
A beneficial consultant to figuring out the matter of quantifying uncertainty in dose reaction kin for poisonous substancesIn brand new medical study, there exists the necessity to tackle the subject of uncertainty because it relates to dose reaction modeling. Uncertainty Modeling in Dose reaction is the 1st publication of its type to enforce and evaluate assorted tools for quantifying the uncertainty within the likelihood of reaction, as a functionality of dose.
Every one ebook has major goals1. confirm baseline concentrations of metals and metalloids in tissues of consultant box populations of estuarine coastal, and open ocean organisms (Book 1:algae and macrophytes, protists, sponges, coelenterates, molluscs, crustaceans, bugs, chaetognaths, annelids, echinoderms, and tunicates) (Book 2: elasmobranchs, fishes, reptiles, birds, mammals) and their value to organism overall healthiness and to the future health in their shoppers.
Dr. Myrtle A. Davis has assembled a panel of state of the art scientists to explain their top equipment for detecting, illuminating, and quantifying apoptotic mechanisms in a manner that's valuable for the layout of toxicology and pharmacology experiences. those state of the art strategies comprise movement cytometric, fluorometric, and laser scanning tools for quantifying and characterizing apoptosis, in addition to protocols for using DNA microarray know-how, excessive throughput monitors, and ELISA.
Biomarkers in Toxicology is a well timed and entire reference devoted to all elements of biomarkers that relate to chemical publicity and their results on organic platforms. This e-book contains either vertebrate and non-vertebrate species types for toxicological trying out and improvement of biomarkers.
- Genetic Toxicology and Cancer Risk Assessment
- Allergens and respiratory pollutants: The role of innate immunity
- Analysis of Hazardous Substances in Air
- Toxicogenomics and proteomics
Extra resources for Drug Discovery and Evaluation: Pharmacological Assays
Influence on Lipoprotein- Lipase Activity . . . . . Influence on Several Steps of Cholesterol Absorption and Formation . . . . . Inhibition of Cholesterol Biosynthesis . . . . . . General Considerations on Cholesterol Biosynthesis . . Determination of HMG-CoA-Reductase Inhibitory Activity General Considerations on HMG-CoA-Reductase . . . Inhibition of the Isolated Enzyme HMG-CoA-Reductase in Vitro . . . . . . . . Inhibition of the Incorporation of 14 C-Sodium Acetate into Cholesterol in Isolated Liver Cells .
Determination of Advanced Glycation End Products (AGE) . Measurement of Reactive Oxygen Species (ROS) Production . Insulin Analogs: Assessment of Insulin Mitogenicity and IGF-I Activity . . . . . . . . . . . . Introduction and Application to Insulin Analogs . . . . Insulin Receptor Affinity . . . . . . . . . . Signaling Via Insulin Receptor . . . . . . . . . IGF-I Receptor Affinity . . . . . . . . . . . Signaling via IGF-1 Receptor . . . .
Safety Pharmacology of Drugs with Anti-obesity Activity . . . . . . . 1609 1609 1610 1612 1613 1613 1614 1614 1614 1617 1621 1622 1622 1622 . . . . . . . 1625 1625 1629 1629 1630 1633 1635 1636 1636 1639 1639 1641 1642 1643 . . . . . . . 1643 1645 1650 1650 1651 1652 1652 1652 1655 1657 1657 1658 1659 1660 Contents XLIII Chapter M Anti-Atherosclerotic Activity . . . . . . . . . . . . . 7 Induction of Experimental Atherosclerosis . . . . General Considerations .